Anika Therapeutics Inc. (NASDAQ:ANIK) released its earnings results on Wednesday. The company reported $0.57 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.13.
ANIK has been the topic of several recent analyst reports. Zacks Investment Research cut Anika Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 29th. Northland Securities cut Anika Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, April 27th.
Shares of Anika Therapeutics (NASDAQ:ANIK) traded up 1.45% during midday trading on Wednesday, hitting $52.58. The stock had a trading volume of 117,441 shares. The firm has a 50 day moving average of $51.37 and a 200-day moving average of $45.24. The company has a market cap of $753.47 million and a P/E ratio of 23.58. Anika Therapeutics has a one year low of $30.93 and a one year high of $54.96.
Anika Therapeutics, Inc develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. The Company’s products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. The Company’s wholly owned subsidiary Anika S.r.l., has about 20 products commercialized primarily in Europe.
